Built on unique RNA science and cutting-edge AI, Viome's at-home test redefines health by analyzing 100 million biomarkers to detect early signs of biological dysfunction linked to 25+ chronic health ...

While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Charlotte Schubert on Nov 10, 2021 ...

Inside our bodies lies a flourishing ecosystem of microorganisms. This microbiome of bacteria and viruses has a powerful impact on our health, but the exact nuances of how are still being filled in.

Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous ...

Viome CEO Naveen Jain shows how to put a stool sample into a kit for analysis. (GeekWire Photo / Alan Boyle) Viome, the wellness startup founded by Seattle-based tech entrepreneur Naven Jain, has ...

A collaboration between Viome Life Sciences and Scripps Research is set to develop and clinically validate the first ribonucleic acid (RNA) test aimed at detecting precancerous colon polyps. This ...

With its recently bestowed breakthrough device designation positioning Viome Life Sciences’ mRNA analysis platform firmly in the FDA’s good graces, the gut-testing company has raised $54 million to ...

Add Yahoo as a preferred source to see more of our stories on Google. Research on the human microbiome -- microorganism communities that live in a part of your body such as your mouth or gut -- has ...

More than half of adult in the United States have at least ine chronic condition, and more than a quarter have multiple. That includes arthritis, cancer, chronic obstructive pulmonary disease (COPD), ...

Viome Life Sciences, a biotechnology company, received $86.5 million in an oversubscribed Series C funding round, which it will use to grow its business, the company announced Friday. The Bellevue, ...